Accessibility Menu
Korro Bio logo

Korro Bio

(NASDAQ) KRRO

Current Price$12.14
Market Cap$177.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-21%
5 Year-97%
1 Year-7%
1 Month+15%
Korro Bio last closing stock price
MetricPriceDate
Last closeUSD 12.282026-07-16
Korro Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-14.13%USD 14.302026-07-09
1 month+15.2%USD 10.662026-06-16
3 month-14.66%USD 14.392026-04-17
Year to date+53.31%USD 8.012025-12-31
1 year-6.69%USD 13.162025-07-16
3 year-60.39%USD 31.002023-07-17
5 year-96.93%USD 399.502021-07-16
Since inception-20.67%USD 15.482023-11-06

Korro Bio Financials at a Glance

Market Cap

$177.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.84M

Net Income (TTM)

-$113.50M

EPS (TTM)

-$11.68

P/E Ratio

-1.05

Dividend

$0.00

Beta (Volatility)

1.50 (Average)

Price

$12.14

Volume

2,812

Open

$11.78

Previous Close

$12.28

Daily Range

$11.76 - $12.21

52-Week Range

$5.20 - $55.89

Estimated Earnings Date

Aug 11, 2026

KRRO News

individual-investor-stock-chart-at-home-getty

These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?

Cory RenauerDec 2, 2023

KRRO: Motley Fool Moneyball Superscore

40

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Korro Bio

Korro Bio develops medicines that edit RNA to treat genetic diseases. Its main focus is on rare and common illnesses, such as lung and liver disorders. The company’s work aims to help people with conditions that currently have limited treatment options.

RNA Remedies: What Korro Bio Sells

  • KRRO-110 (AATD therapy): Lead drug candidate for Alpha-1 Antitrypsin Deficiency, a rare genetic lung and liver disease. (100% of revenue from collaborations, not product sales)
  • Pipeline Programs: Early-stage research for rare metabolic disorders, amyotrophic lateral sclerosis (ALS), and pain conditions.
  • OPERA Platform: Proprietary technology for editing RNA, aiming to correct disease-causing genetic errors.
  • Collaboration Revenue: Income from research partnerships, mainly with pharmaceutical companies. (100% of reported revenue as of June 2025)

Growth Spurts and Strategic Moves

  • Launched Phase 1/2a clinical trial for KRRO-110 in 2025.
  • Formed a research and license partnership with Novo Nordisk in September 2024.
  • Signed a delivery technology agreement with Genevant Sciences in March 2023.
  • Announced a new rare metabolic disorder program, with a candidate expected by end of 2025.
  • Reduced workforce by 19% in May 2025 to streamline operations.

What Makes Korro Bio Stand Out

Korro Bio uses RNA editing, which changes genetic messages without altering DNA. This approach may offer more precise and temporary treatments for genetic diseases. The company partners with larger firms to access delivery technology and expand its reach.

Five Things You Need to Know

  • Revenue was $1.5 million in Q2 2025, all from collaborations.
  • Net loss was $27 million in Q2 2025, down 12.8% from Q2 2024.
  • Cash and investments fell 61.4% to $119.6 million in Q2 2025.
  • Research and development spending was $21.0 million in Q2 2025, up from $17.1 million in Q2 2024.

Bottom Line

Korro Bio is an early-stage biotech focused on RNA editing for genetic diseases. The company relies on partnerships and collaboration revenue as it advances its drug pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

49

CEO

Ram Aiyar, PhD, MBA

Website

www.korrobio.com

Headquarters

Cambridge, MA 02139-1562, US

KRRO Financials

Key Financial Metrics (TTM)

Gross Margin

73.22%

Operating Margin

-2154.03%

Net Income Margin

-2954.14%

Return on Equity

-117.86%

Return on Capital

-92.01%

Return on Assets

-61.81%

Earnings Yield

-95.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$177.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

14.42M

Volume

2.81K

Avg. Volume

181.26K

Financials (TTM)

Gross Profit

$2.81M

Operating Income

-$82.76M

EBITDA

-$78.15M

Operating Cash Flow

-$70.18M

Capital Expenditure

-$420.00K

Free Cash Flow

-$70.60M

Cash & ST Invst.

$113.97M

Total Debt

$42.89M

Korro Bio Performance Analysis

Korro Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 2,271,000N/A
20252025-12-31USD 6,392,000181.5%
Korro Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-42.7%
Q32025-09-30-25.3%
Q42025-12-3118.5%
Q12026-03-31-100.0%
Korro Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -227.4284.5%
20232023-12-31USD -53.08-76.7%
20242024-12-31USD -9.37-82.3%
20252025-12-31USD -12.4833.2%
Korro Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-10.0%
Q32025-09-3029.9%
Q42025-12-31-177.6%
Q12026-03-3168.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$380.00K

-114.9%

Gross Margin

0.00%

N/A

Market Cap

$177.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.61M

N/A

Employees

49

N/A

Net Income

-$19.63M

+16.1%

EBITDA

-$20.06M

+15.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$113.97M

-0.9%

Total Debt

$42.89M

-5.1%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$40.08M

-6.5%

Short Term Debt

$2.80M

+21.5%

Return on Assets

-61.81%

N/A

Return on Invested Capital

-49.02%

N/A

Free Cash Flow

-$16.10M

+34.5%

Operating Cash Flow

-$16.07M

+34.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALTAltimmune, Inc.
$2.90+1.75%
ENGNenGene Holdings Inc.
$1.90-1.04%
AMRNAmarin Corporation plc
$14.18+0.49%
LRMRLarimar Therapeutics, Inc.
$3.62-1.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$67.07-0.05%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.44-0.00%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$42.99+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.36-0.05%

Questions About KRRO

What is the current price of Korro Bio?

Korro Bio is trading at $12.14 per share.

What is the 52-week range for Korro Bio?

Over the past 52 weeks, Korro Bio has traded between $5.20 and $55.89.

How much debt does Korro Bio have?

As of the most recent reporting period, Korro Bio reported total debt of $42.89M.

How much cash does Korro Bio have on hand?

Korro Bio reported $62.70M in cash and cash equivalents in its most recent financial results.

What is Korro Bio’s dividend yield?

Korro Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services